Jin Medical International Ltd

Jin Medical International Ltd (NASDAQ: ZJYL) is a holding entity primarily focused on the design and production of wheelchairs. Operating through its wholly owned subsidiaries, the company specializes in the design, development, and manufacturing, and distribution of wheelchairs and other mobility aid products intended for individuals with disabilities or limited mobility.

Positive Growth Aspects

• Strong Market Focus and Global Reach: Jin Medical International Ltd., through its VIE Changzhou Zhongjin, has built a strong specialization in wheelchair design and manufacturing, with over 96% of its revenue consistently derived from this segment. The company boasts a diversified global presence, selling products in Japan, China, the U.S., Canada, Australia, Korea, Israel, and Singapore. It has developed a reputation for quality, with a broad product lineup of over 30 manual wheelchair models catering to various price points and needs. The company’s long-term relationship with Nissin Medical Industries, its largest distributor in Japan, has provided consistent revenue and brand recognition in one of the world’s largest aged demographics.
• Innovation and Robust R&D Foundation: Jin Med’s success is bolstered by a dedicated R&D team of 56 members, including many with advanced degrees, and led by an award-winning CEO, Dr. Erqi Wang. The company holds 106 patents, with 22 more pending, underscoring a strong innovation pipeline. New product developments, such as lightweight electric wheelchairs and portable oxygen concentrators, reflect its commitment to evolving customer needs. These innovations are strategically positioned to tap into the expanding elderly populations in both Japan and China, further supported by macroeconomic trends like rising healthcare spending and active lifestyles among seniors.

Growth Challenges

• Heavy Customer Concentration Risk: Despite its global presence, Jin Medical faces significant customer concentration risk, with approximately 73.0% and 78.2% of its total revenue in fiscal years 2022 and 2021, respectively, derived from a single customer, Nissin Medical Industries. Including subsidiaries like Nissin Korea and Nissin Vietnam, the concentration rises even further. This dependency exposes the company to considerable revenue volatility and operational risk if any disruption or strategic shift occurs in its relationship with Nissin.
• Limited Diversification in Product Mix and Sales Channels: While the company has begun exploring electric wheelchairs and living aids such as oxygen concentrators and bathing machines, these products collectively contributed less than 4% of revenue in recent fiscal years. The overwhelming reliance on manual wheelchairs limits diversification. Furthermore, distribution is entirely reliant on third-party dealers, with no direct-to-consumer model or retail presence, potentially restricting brand control and margins. Additionally, the company’s 2022 revenue saw a 7.6% decline due to pandemic-related disruptions, highlighting its vulnerability to external shocks and regional challenges.

Technical Observation (on the daily chart):

ZJYL has been in a sustained downtrend over the past year, with the price consistently trading below its 21-day and 50-day moving averages, currently at USD 0.66 and USD 0.75 respectively. The RSI is near oversold levels at 34.8, indicating weak buying momentum, while trading volume remains low. Overall, the technical setup reflects continued bearish sentiment with no clear signs of reversal.

Jin Medical International Ltd. demonstrates strong market specialization in manual wheelchairs, supported by a robust R&D foundation, global reach, and long-standing partnerships—most notably with Nissin in Japan. Its commitment to innovation and the growing aging populations in key markets like China and Japan position it well for long-term demand growth. However, the company faces notable risks, including high revenue dependence on a single customer, limited diversification in its product mix, and vulnerability to regional disruptions such as the COVID-19 resurgence in 2022. While its foundation is solid, its growth trajectory hinges on successful product expansion and reduced customer concentration.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Jin Medical International Ltd (NASDAQ: ZJYL) at the closing market price of USD 0.58 as of July 08,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is July 08,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.